Evidence map›Paper›PMID 30947753›Full record

Observational studyCritical care (London, England)2019

Sequential organ failure assessment score is an excellent operationalization of disease severity of adult patients with hospitalized community acquired pneumonia - results from the prospective observational PROGRESS study.

Peter Ahnert, Petra Creutz, Katrin Horn, Fabian Schwarzenberger, Michael Kiehntopf, Hamid Hossain, Michael Bauer, Frank Martin Brunkhorst, Konrad Reinhart, Uwe Völker and 6 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02782013 (Study of Progression of Hospitalized Community Acquired Pneumonia - Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02782013 completednot on this map

Study of Progression of Hospitalized Community Acquired Pneumonia - Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis

TypeobservationalSponsorPneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe SepsRan2009 to 2022Enrolled2,309ConditionsPneumonia, Sepsis, Shock, Septic
3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Borderline microscopic organism and lockdown impacted across the borders-global shakers.Environmental science and pollution research international · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. External Validation and Recalibration of the CURB-65 and PSI for Predicting 30-Day Mortality and Critical Care Intervention in Multiethnic Patients with COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Peter AhnertUniversity of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Härtelstr. 16-18, 04107, Leipzig, Germany. peter.ahnert@imise.uni-leipzig.de.ORCID 0000-0002-1771-0856
Petra CreutzDepartment of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchowklinikum, Augustenburgerplatz 1, 13353, Berlin, Germany.
Katrin HornUniversity of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Härtelstr. 16-18, 04107, Leipzig, Germany.
Fabian SchwarzenbergerFaculty of Informatics / Mathematics, HTW Dresden University of Applied Sciences, Friedrich-List-Platz 1, 01069, Dresden, Germany.
Michael KiehntopfJena University Hospital, Integrated Biobank Jena (IBBJ) and Institute of Clinical Chemistry and Laboratory Diagnostics, Am Klinikum 1, 07740, Jena, Germany.
Hamid HossainTechnische Hochschule Mittelhessen, University of Applied Sciences, Life Science Engineering, Wiesenstr. 14, 35390, Gießen, Germany.
Michael BauerDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Frank Martin BrunkhorstCenter for Clinical Studies and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Konrad ReinhartJena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Uwe VölkerDepartment Functional Genomics, Interfaculty Institute of Genetics and Functional Genomics, University Medicine Greifswald, Felix-Hausdorff-Str. 8, 17475, Greifswald, Germany.
Trinad ChakrabortyUniversity Hospital Giessen, Institute for Medical Microbiology, Schubertstr. 81, 35392, Gießen, Germany.
Martin WitzenrathDepartment of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Markus LöfflerDepartment of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Norbert SuttorpDepartment of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Markus ScholzUniversity of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Härtelstr. 16-18, 04107, Leipzig, Germany.
PROGRESS Study Group

Funding

Bundesministerium für Bildung und Forschung 01KI07110Bundesministerium für Bildung und Forschung 01KI07111Bundesministerium für Bildung und Forschung 01KI07113Bundesministerium für Bildung und Forschung 01KI07114Bundesministerium für Bildung und Forschung 01KI1010DBundesministerium für Bildung und Forschung 01KI1010IDeutsche Zentrum für Lungenforschung 82DZLJ19A2
6 · The paper itself

Abstract

backgroundCAP (Community acquired pneumonia) is frequent, with a high mortality rate and a high burden on health care systems. Development of predictive biomarkers, new therapeutic concepts, and epidemiologic research require a valid, reproducible, and quantitative measure describing CAP severity.

methodsUsing time series data of 1532 patients enrolled in the PROGRESS study, we compared putative measures of CAP severity for their utility as an operationalization. Comparison was based on ability to correctly identify patients with an objectively severe state of disease (death or need for intensive care with at least one of the following: substantial respiratory support, treatment with catecholamines, or dialysis). We considered IDSA/ATS minor criteria, CRB-65, CURB-65, Halm criteria, qSOFA, PSI, SCAP, SIRS-Score, SMART-COP, and SOFA.

resultsSOFA significantly outperformed other scores in correctly identifying a severe state of disease at the day of enrollment (AUC = 0.948), mainly caused by higher discriminative power at higher score values. Runners-up were the sum of IDSA/ATS minor criteria (AUC = 0.916) and SCAP (AUC = 0.868). SOFA performed similarly well on subsequent study days (all AUC > 0.9) and across age groups. In univariate and multivariate analysis, age, sex, and pack-years significantly contributed to higher SOFA values whereas antibiosis before hospitalization predicted lower SOFA.

conclusionsSOFA score can serve as an excellent operationalization of CAP severity and is proposed as endpoint for biomarker and therapeutic studies.

trial registrationclinicaltrials.gov NCT02782013 , May 25, 2016, retrospectively registered.

Indexed as

Organ Dysfunction ScoresAdultAgedCommunity-Acquired InfectionsFemaleGermanyHospitalizationHumansMaleMiddle AgedPneumoniaPrognosisProspective StudiesRetrospective StudiesSeverity of Illness IndexTime and Motion StudiesBiomarkerClinical epidemiologyInfectious diseaseLung diseaseProspective clinical studySeverity score

Identifiers

PMID30947753
PMCPMC6450002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.